Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Changing the game — aiming to cure. We were founded to bring novel, life-changing therapies to patients suffering from autoimmune and inflammatory diseases with high unmet medical need.
News
Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit
San Diego, CA, and Bergisch Gladbach, Germany - September 15, 2026 - Tr1X, Inc. and Miltenyi Biotec today announced that they will highlight their collaboration to support the development and manufacturing of Tr1X's allogeneic Tr1 and CAR-Tr1 Treg cell th
Read more
Report
Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit - Biotech Spain
Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit
Read more
Report
CIRM approves more than $60 million to support clinical and preclinical development awards
South San Francisco, CA, June 25, 2026 - The California Institute for Regenerative Medicine (CIRM) governing board today approved funding of over $40 million for four new preclinical development awards and nearly $21 million to support three clinical tria
Read more
Report
Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026
SAN DIEGO-(BUSINESS WIRE)-Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease company developing Type 1 regulatory T (Tr1) cell therapies, today announced two oral presentations at the American Society of Gene and Cell Therapy Annual Meeting
Read more
Report
Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026
Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026
Read more
Report
Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD
In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and efficacy The post Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD appeared first on Tr1X Bi
Read more
Report
Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103
First clinical data from Phase 1 dose-escalation study in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). TRX103 demonstrated exceptional safety, accelerated immune reconstitution, and dose-dependent persistence and indu
Read more
Report
Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103 First clinical data from Phase 1 dose-escalation study in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). TRX103 demonstrated exceptional Press Releases February 4, 2026
Read more
Report
The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X's pipeline of Type-1 regulatory T cells
The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X's pipeline of Type-1 regulatory T cells The post The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X's pipeline of Type-1 regulatory T cells appeared first on Tr
Read more
Report
Scaling Smarter: a Case Study in Overcoming Cell Therapy Manufacturing & Regulatory Hurdles
Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a case study in overcoming cell therapy manufacturing and regulatory hurdles" The post Scaling Smarter: a Case Study in Overcoming Cell Therapy Manufacturing & Regulatory Hurdles appeared first
Read more
Report
Show more news